Jadpro: Managing Classical Hodgkin Lymphoma With Antibodydrug Conjugates

Amy Goodrich, RN, MSN, CRNP-AC, and Nadia Khan, MD, discuss the role of antibody–drug conjugates in the treatment of classical Hodgkin lymphoma, including mechanism of action, recent approvals, emerging data, and expert guidance on clinical application.Instructions for CE credit:If you would like to earn credit, you must take the pre-test first by visiting https://education.annenberg.net/5701-EM1To finish earning credit, you must take the post-test by visiting https://education.annenberg.net/node/9807/take/1

Amy Goodrich, RN, MSN, CRNP-AC, and Kevin Nguyen, a patient who was treated for classical Hodgkin lymphoma, discuss his treatment journey from diagnosis through relapse and how shared decision-making between him and his health-care team played an important role in the process.Instructions for CE credit:If you would like to earn credit, you must take the pre-test first by visiting https://education.annenberg.net/5701-EM3To finish earning credit, you must take the post-test by visiting https://education.annenberg.net/node/9817/take/1

Amy Goodrich, RN, MSN, CRNP-AC, and Barbara Rogers, CRNP, MN, AOCN®, ANP-BC, review best practices for anticipating and managing side effects for patients being treated for classical Hodgkin lymphoma, including the short- and long-term adverse events associated with chemotherapy, checkpoint inhibitors, and antibody–drug conjugates.Instructions for CE credit:If you would like to earn credit, you must take the pre-test first by visiting https://education.annenberg.net/5701-EM2To finish earning credit, you must take the post-test by visiting https://education.annenberg.net/node/9812/take/1